Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 15/20 | 0.70 |
| ▸ | LOXL2 | Q9Y4K0 | 9/20 | 0.70 |
| ▸ | MAOA | P21397 | 2/20 | 0.70 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13067635 | 0.83 | LOX (0.54) | LOXLOXL2MAOA | |
| SCHEMBL19274253 | 0.82 | LOX (1.00) | LOXLOXL2MAOALOXL3KCNH2 | |
| SCHEMBL19259887 | 0.81 | LOX (1.00) | LOXLOXL2MAOALOXL3KCNH2 | |
| SCHEMBL19274688 | 0.80 | LOX (0.65) | LOXLOXL2MAOALOXL3KCNH2 | |
| SCHEMBL9971313 | 0.76 | HTR6 (0.56) | LOXLOXL2MAOAHTR6LOXL3 | |
| SCHEMBL14572440 | 0.76 | HTR6 (0.56) | LOXLOXL2MAOAHTR6LOXL3 | |
| SCHEMBL18643569 | 0.75 | LOX (0.59) | LOXLOXL2MAOA | |
| SCHEMBL19274537 | 0.73 | LOX (1.00) | LOXLOXL2MAOALOXL3KCNH2 | |
| SCHEMBL4648549 | 0.73 | CA2 (0.47) | LOXLOXL2MAOA | |
| SCHEMBL3005886 | 0.73 | L3MBTL1 (0.43) | LOXLOXL2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960408-B2 | Quinolinyl and benzothiazolyl modulators | AMGEN INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090221635-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | AMGEN INC. (US) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221635-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | PPARG, PPARA, PPARD | LOX 2320/4885LOXL2 3120/4885MAOA 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.